Neurocrine Biosciences(NBIX)

SAN DIEGO, CABiotechnology1 H-1B visas (FY2023)

Focus: Neurocrine Biosciences is a San Diego-based biotech company with 1,001-5,000 employees generating $1.9B in FY2025 revenue, primarily from its flagship neurology and psychiatry franchise. The company operates as a pure-play CNS specialist with a diversified pipeline across movement disorders, psychiatry, and rare neurological conditions.

Profile data last refreshed 17h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

152+24 this month

Hot — 114 jobs added in 30d

Net +24 (114 new, 90 removed). Aggressive expansion phase.

Should You Work at Neurocrine Biosciences?

AI assessment

Neurocrine is a career-stage match for specialists in rare CNS disease who value deep therapeutic expertise and near-term pipeline catalysts over diversified business risk.

Why Work Here

High revenue concentration ($1.7B Part D spending on INGREZZA) provides stability and deep expertise in a differentiated market; INGREZZA has patent protection until 2040

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.9B

Key Products

INGREZZA

Tardive Dyskinesia (primary indication; additional indications in pipeline)

$1.7B

Peak

Help build intelligence for Neurocrine Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Ag

Tardive Dyskinesia

N/A

Clinical Trials (1)

NCT03062033Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

N/A

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

Parkinson's Disease

N/A

Clinical Trials (1)

NCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

N/A

Telemedicine Consult

Drug-Induced Movement Disorder

N/A

Clinical Trials (1)

NCT06060444Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

N/A

Opicapone

Parkinson Disease

N/A

Clinical Trials (1)

NCT04787965Opicapone Treatment Initiation Open-Label Study

N/A

exposure to healthcare transition protocol

Congenital Adrenal Hyperplasia

N/A

Clinical Trials (1)

NCT07611786Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

N/A

VY-AADC01

Idiopathic Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT03065192Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Phase 1

NBI-98854

Tourette Syndrome

Phase 1

Clinical Trials (1)

NCT02256475Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase 1

Amphetamine

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02959892A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

Phase 1

DITEST

Male Hypogonadism

Phase 1

Clinical Trials (1)

NCT02966652Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism

Phase 1

Infacort

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03178214Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration

Phase 1

TAK-831 Oral Tablet

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04234672A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Phase 1

Dexamethasone

Healthy

Phase 1

Clinical Trials (1)

NCT02408068Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only

Phase 1

Valbenazine

Tardive Dyskinesia

Phase 1

Clinical Trials (1)

NCT05053321Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

Phase 1

TAK-831

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03687684Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Phase 1

Infacort®

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03311932A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

Phase 1

NBI-98854 50 mg capsule once daily

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

Phase 1

Clinical Trials (1)

NCT01910480Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Phase 1

TAK-831 T2

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03706469A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Phase 1

TAK-831

Healthy

Phase 1

Clinical Trials (1)

NCT02716987Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

Phase 1

TAK-831 Tablet T2

Healthy

Phase 1

Clinical Trials (1)

NCT03224325A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Phase 1

TAK-653 Placebo

Depressive Disorder

Phase 1

Clinical Trials (1)

NCT02561156TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Phase 1

Chronocort®

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03343327A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects

Phase 1

Infacort

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02777268Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone

Phase 1

NBI-98854 50 mg capsule

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Phase 1

Clinical Trials (1)

NCT01916993Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Phase 1

Hydrocortisone

Congenital Adrenal Hyperplasia

Phase 1

Clinical Trials (1)

NCT03019614An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

Phase 1

Chronocort

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT03051893A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

Phase 1

Opicapone

Parkinson Disease

Phase 1

Clinical Trials (1)

NCT03496870A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Phase 1

NBI-77860

Congenital Adrenal Hyperplasia

Phase 1

Clinical Trials (1)

NCT02349503Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Phase 1

interleukin-4 PE38KDEL cytotoxin

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00039052Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Phase 1

TAK-041

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02748694Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Phase 1

TAK-653

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03792672A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Phase 1

TAK-831 Oral Suspension

Schizophrenia, Cerebellar Ataxia

Phase 1

Clinical Trials (1)

NCT02566759A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Phase 1

Hydrocortisone granules

Adrenal Insufficiency

Phase 1

Clinical Trials (1)

NCT01960530An Investigational Study of Hydrocortisone

Phase 1

TAK-831

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03101293A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Phase 1

VY-AADC01

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT01973543Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Phase 1

Elagolix

Folliculogenesis

Phase 1

Clinical Trials (1)

NCT01403038An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Phase 1

NBI-6024

Type 1 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT00873561A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

Phase 1

VY-AADC02

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT03562494VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

Phase 1

Chronocort

Congenital Adrenal Hyperplasia

Phase 1/2

Clinical Trials (1)

NCT00519818Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Phase 1/2

NBI-98854

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT01688037NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Phase 2

NBI-921352

Focal Onset Seizure

Phase 2

Clinical Trials (1)

NCT05159908A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase 2

NBI-98854

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT01267188Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Phase 2

Placebo

Major Depressive Disorder

Phase 2

Clinical Trials (2)

NCT07832383Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor

Phase 2

NCT05203341Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

NBI-1117568

Schizophrenia

Phase 2

Clinical Trials (1)

NCT05545111Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

Phase 2

NBI-827104

Essential Tremor

Phase 2

Clinical Trials (1)

NCT04880616Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

Phase 2

TAK-041

Stable Schizophrenia

Phase 2

Clinical Trials (1)

NCT03319953A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

Phase 2

NBI-98854

Tourette Syndrome

Phase 2

Clinical Trials (1)

NCT03732534Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Phase 2

NBI-1065890

Tardive Dyskinesia

Phase 2

Clinical Trials (1)

NCT07365462Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Phase 2

Luvadaxistat

Schizophrenia

Phase 2

Clinical Trials (1)

NCT03382639A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

Phase 2

Valbenazine

Tourette Syndrome

Phase 2

Clinical Trials (1)

NCT03530293Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Phase 2

NBI-827104

Epileptic Encephalopathy

Phase 2

Clinical Trials (1)

NCT04625101Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase 2

Neurocrine Biosciences(NBIX)

Should You Work at Neurocrine Biosciences?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Open Jobs (152)

Space Planning Manager

NeuroPsych Account Specialist- Tucson AZ

Executive Assistant, Quality Regulatory and Medical Writing

NeuroPsych Account Specialist - Oshkosh WI

Sr. Manager, HEOR

Director, Standards & Integrations

Regional Patient Access Manager, South Florida

Clinical Site Contracts and Budget Administrator

Sr. Commercial Manufacturing API Manager

NeuroPsych Account Specialist - Sioux City IA

Sr. Analyst, Field Operations

NeuroPsych Account Specialist - San Francisco CA

Senior Talent Acquisition Coordinator | Onsite FT Temporary

Sr. Administrative Assistant, Drug Safety

Facilities Coordinator II

Facilities Technician I

Sr. Facilities Technician

Rare Disease Account Specialist - CAH, Milwaukee, WI

NeuroPsych Account Specialist - Baton Rouge, LA

Sr. Medical Science Liaison – Northeast

Rare Disease Account Specialist – CAH, Westchester, NY

Vivarium Tech II

Principal Data Engineer, Biometrics

NeuroPsych Account Specialist - Richmond, KY

Rare Disease Account Specialist - CAH, Manhattan, NY

Financials (FY2025)

Hiring Trend

Visa Sponsorship